These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 19724041)

  • 1. Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial.
    Montalescot G; Cayla G; Collet JP; Elhadad S; Beygui F; Le Breton H; Choussat R; Leclercq F; Silvain J; Duclos F; Aout M; Dubois-Randé JL; Barthélémy O; Ducrocq G; Bellemain-Appaix A; Payot L; Steg PG; Henry P; Spaulding C; Vicaut E;
    JAMA; 2009 Sep; 302(9):947-54. PubMed ID: 19724041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
    Kastrati A; Mehilli J; Neumann FJ; Dotzer F; ten Berg J; Bollwein H; Graf I; Ibrahim M; Pache J; Seyfarth M; Schühlen H; Dirschinger J; Berger PB; Schömig A;
    JAMA; 2006 Apr; 295(13):1531-8. PubMed ID: 16533938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognosis of patients with non-ST-segment-elevation myocardial infarction and nonobstructive coronary artery disease: propensity-matched analysis from the Acute Catheterization and Urgent Intervention Triage Strategy trial.
    Planer D; Mehran R; Ohman EM; White HD; Newman JD; Xu K; Stone GW
    Circ Cardiovasc Interv; 2014 Jun; 7(3):285-93. PubMed ID: 24847016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early versus delayed invasive intervention in acute coronary syndromes.
    Mehta SR; Granger CB; Boden WE; Steg PG; Bassand JP; Faxon DP; Afzal R; Chrolavicius S; Jolly SS; Widimsky P; Avezum A; Rupprecht HJ; Zhu J; Col J; Natarajan MK; Horsman C; Fox KA; Yusuf S;
    N Engl J Med; 2009 May; 360(21):2165-75. PubMed ID: 19458363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial.
    Schömig A; Mehilli J; Antoniucci D; Ndrepepa G; Markwardt C; Di Pede F; Nekolla SG; Schlotterbeck K; Schühlen H; Pache J; Seyfarth M; Martinoff S; Benzer W; Schmitt C; Dirschinger J; Schwaiger M; Kastrati A;
    JAMA; 2005 Jun; 293(23):2865-72. PubMed ID: 15956631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.
    Stone GW; Bertrand ME; Moses JW; Ohman EM; Lincoff AM; Ware JH; Pocock SJ; McLaurin BT; Cox DA; Jafar MZ; Chandna H; Hartmann F; Leisch F; Strasser RH; Desaga M; Stuckey TD; Zelman RB; Lieber IH; Cohen DJ; Mehran R; White HD;
    JAMA; 2007 Feb; 297(6):591-602. PubMed ID: 17299194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
    Ferguson JJ; Califf RM; Antman EM; Cohen M; Grines CL; Goodman S; Kereiakes DJ; Langer A; Mahaffey KW; Nessel CC; Armstrong PW; Avezum A; Aylward P; Becker RC; Biasucci L; Borzak S; Col J; Frey MJ; Fry E; Gulba DC; Guneri S; Gurfinkel E; Harrington R; Hochman JS; Kleiman NS; Leon MB; Lopez-Sendon JL; Pepine CJ; Ruzyllo W; Steinhubl SR; Teirstein PS; Toro-Figueroa L; White H;
    JAMA; 2004 Jul; 292(1):45-54. PubMed ID: 15238590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early or late intervention in high-risk non-ST-elevation acute coronary syndromes: results of the ELISA-3 trial.
    Badings EA; The SH; Dambrink JH; van Wijngaarden J; Tjeerdsma G; Rasoul S; Timmer JR; van der Wielen ML; Lok DJ; van 't Hof AW
    EuroIntervention; 2013 May; 9(1):54-61. PubMed ID: 23685295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial.
    ; Steg PG; Jolly SS; Mehta SR; Afzal R; Xavier D; Rupprecht HJ; López-Sendón JL; Budaj A; Diaz R; Avezum A; Widimsky P; Rao SV; Chrolavicius S; Meeks B; Joyner C; Pogue J; Yusuf S
    JAMA; 2010 Sep; 304(12):1339-49. PubMed ID: 20805623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes.
    Montalescot G; Bolognese L; Dudek D; Goldstein P; Hamm C; Tanguay JF; ten Berg JM; Miller DL; Costigan TM; Goedicke J; Silvain J; Angioli P; Legutko J; Niethammer M; Motovska Z; Jakubowski JA; Cayla G; Visconti LO; Vicaut E; Widimsky P;
    N Engl J Med; 2013 Sep; 369(11):999-1010. PubMed ID: 23991622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early invasive versus selectively invasive management for acute coronary syndromes.
    de Winter RJ; Windhausen F; Cornel JH; Dunselman PH; Janus CL; Bendermacher PE; Michels HR; Sanders GT; Tijssen JG; Verheugt FW;
    N Engl J Med; 2005 Sep; 353(11):1095-104. PubMed ID: 16162880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Outcome of patients with non-ST segment elevation acute coronary syndrome undergoing early or delayed intervention].
    Zhang J; Qiao SB; Zhu J;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Oct; 38(10):865-9. PubMed ID: 21176626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
    Tricoci P; Lokhnygina Y; Berdan LG; Steinhubl SR; Gulba DC; White HD; Kleiman NS; Aylward PE; Langer A; Califf RM; Ferguson JJ; Antman EM; Newby LK; Harrington RA; Goodman SG; Mahaffey KW
    Circulation; 2007 Dec; 116(23):2669-77. PubMed ID: 18025532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome.
    Damman P; Hirsch A; Windhausen F; Tijssen JG; de Winter RJ;
    J Am Coll Cardiol; 2010 Mar; 55(9):858-64. PubMed ID: 20045278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes.
    Riezebos RK; Ronner E; Ter Bals E; Slagboom T; Smits PC; ten Berg JM; Kiemeneij F; Amoroso G; Patterson MS; Suttorp MJ; Tijssen JG; Laarman GJ;
    Heart; 2009 May; 95(10):807-12. PubMed ID: 19098058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial).
    Cox DA; Stone GW; Grines CL; Stuckey T; Zimetbaum PJ; Tcheng JE; Turco M; Garcia E; Guagliumi G; Iwaoka RS; Mehran R; O'Neill WW; Lansky AJ; Griffin JJ;
    Am J Cardiol; 2006 Aug; 98(3):331-7. PubMed ID: 16860018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
    Valgimigli M; Campo G; Percoco G; Bolognese L; Vassanelli C; Colangelo S; de Cesare N; Rodriguez AE; Ferrario M; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Parrinello G; Ferrari R;
    JAMA; 2008 Apr; 299(15):1788-99. PubMed ID: 18375998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
    Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
    Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.
    Bertrand OF; Rodés-Cabau J; Rinfret S; Larose E; Bagur R; Proulx G; Gleeton O; Costerousse O; De Larochellière R; Roy L
    Am J Cardiol; 2009 Nov; 104(9):1235-40. PubMed ID: 19840568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial.
    Ndrepepa G; Kastrati A; Mehilli J; Neumann FJ; ten Berg J; Bruskina O; Dotzer F; Seyfarth M; Pache J; Dirschinger J; Berger PB; Schömig A
    Eur Heart J; 2008 Feb; 29(4):455-61. PubMed ID: 18158289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.